United Therapeutics UTHR Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Product | |||||
| Adcirca | $30M+26.1% | $23.8M-17.6% | $28.9M-30.0% | $41.3M-26.1% | |
| Nebulized Tyvaso | $585.7M-0.2% | $586.8M+16.8% | $502.6M— | —— | |
| Orenitram | $496.9M+14.4% | $434.3M+20.8% | $359.4M+10.6% | $325.1M+6.2% | |
| Remodulin | $526.8M-2.1% | $538.1M+8.8% | $494.8M-1.1% | $500.2M-2.6% | |
| Tyvaso DPI | $1.29B+25.0% | $1.03B+41.4% | $731.1M— | —— | |
| Unituxin | $226.8M-5.0% | $238.7M+20.0% | $198.9M+8.7% | $182.9M-9.6% | |
| Total revenues by Geography | |||||
| ROW | $145.7M+5.8% | $137.7M+9.9% | $125.3M+2.5% | $122.2M+0.7% | |
| U.S. | $3.04B+10.9% | $2.74B+24.4% | $2.2B+21.4% | $1.81B+16.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does United Therapeutics break its business down?
- United Therapeutics (UTHR) reports total revenues by product across 6 parts — Adcirca, Nebulized Tyvaso, Orenitram, Remodulin and Tyvaso DPI. Each is extracted from the segment footnotes and tracked over time.
- Where does United Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in United Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
